Moderna doses first patients in Phase 2/3 study of COVID-19 vaccine in adolescentsMarket Watch • 12/10/20
Is Moderna Stock A Buy As The Covid Vaccine-Maker Awaits Its First Approval?Investors Business Daily • 12/10/20
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in AdolescentsBusiness Wire • 12/10/20
Moderna Analyst Positive On Coronavirus Vaccine Progress, Downgrades Shares On ValuationBenzinga • 12/09/20
Moderna, Inc. (MRNA) Presents at BMO Growth and ESG Conference Call (Transcript)Seeking Alpha • 12/09/20
Here's What Could Make Moderna's COVID Vaccine a Bigger Winner Than Pfizer'sThe Motley Fool • 12/09/20
Switzerland Increases Its Order for Moderna's Coronavirus Vaccine by Two-ThirdsThe Motley Fool • 12/08/20
Moderna climbs 7% as Morgan Stanley says it could fill a vaccine-demand void left by Pfizer (MRNA)Business Insider • 12/08/20
Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to CanadaZacks Investment Research • 12/08/20
Moderna says Swiss government has increased its COVID vaccine order to 7.5 million doses from 4.5 millionMarket Watch • 12/08/20
Pfizer, Moderna Face Public-Relations Hurdle For Covid Vaccines: IBD/TIPP PollInvestors Business Daily • 12/08/20